The commercial launch of Cationorm(R) in Europe and in the United
States by the end 2008, where the product complies with the OTC status, is
a major event for the development of Novagali Pharma. <
Cationorm(R) is a medical device available in France since April 2008. The product is unpreserved and packaged in box of 30 sterile single vials.
A propos de Novagali Pharma : http://www.novagali.com
Novagali Pharma is an ophthalmic pharmaceutical company based in the Genopole biocluster in Evry (France) that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma has 50 employees.
|SOURCE Novagali Pharma|
Copyright©2008 PR Newswire.
All rights reserved